동물용 정형외과 의약품 시장 기회, 성장 촉진 요인, 산업 동향 분석, 예측(2025-2034년)

The Global Veterinary Orthopedic Medicine Market was valued at USD 3.5 billion in 2024 and is estimated to grow at a CAGR of 8.6% to reach USD 7.9 billion by 2034. This growth is driven by the rising prevalence of orthopedic conditions in both companion and livestock animals, coupled with rapid innovations in biologics and regenerative therapies. As pet ownership rises globally and livestock healthcare gains greater attention, the demand for effective orthopedic solutions continues to surge. Advancements in veterinary diagnostics, preventive care, and pain management solutions are pushing owners to seek early intervention, enhancing long-term outcomes in animal care. Modern pet owners are increasingly prioritizing the overall wellness of their animals, recognizing the importance of mobility and quality of life as pets age. Improved accessibility to veterinary specialists, increasing insurance penetration for animal healthcare, and the booming trend of pet humanization are creating new opportunities for veterinary orthopedic solutions. Furthermore, the strong focus on minimally invasive procedures and cutting-edge regenerative therapies is setting a new standard in treatment protocols. As technology integration deepens, orthopedic medicine for animals is rapidly evolving, creating a dynamic landscape for clinicians, researchers, and pharmaceutical companies alike.

Minimally invasive treatment methods are rapidly transforming the veterinary orthopedic care landscape. Techniques such as viscosupplementation, platelet-rich plasma (PRP) therapy, and stem cell-based regenerative medicine are witnessing widespread adoption thanks to their lower risk of complications and faster post-treatment recovery. These therapies are particularly valuable for managing chronic orthopedic conditions, offering sustained relief without the need for extensive surgical intervention. At the same time, pharmaceutical solutions continue to play a crucial role in daily veterinary care. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, and emerging disease-modifying osteoarthritis drugs (DMOADs) help control pain, reduce inflammation, and improve overall joint function in animals suffering from musculoskeletal disorders.

The pharmaceutical segment generated USD 1.45 billion in 2023, underscoring its pivotal role in orthopedic care. Technology is further reshaping the market, with AI-enabled mobility assessment tools, wearable monitors, and advanced imaging platforms enabling faster diagnosis and more personalized treatment plans. Growing awareness among pet owners about orthopedic issues, coupled with better access to rehabilitation therapies, is fueling interest in specialized orthopedic interventions. Developments in biologics, novel pharmaceuticals, and precision therapies will continue to redefine treatment standards, driving market expansion over the next decade.

In 2024, the companion animals segment held a dominant 72% market share, reflecting the growing number of pets diagnosed with joint conditions like arthritis and ligament injuries. As veterinary healthcare advances and pets live longer, age-related degenerative diseases are becoming more prevalent. Rehabilitation options such as hydrotherapy and physiotherapy are increasingly available and often covered by pet insurance, making advanced orthopedic care more accessible.

The United States veterinary orthopedic medicine market accounted for a 40.1% share in 2024 and is projected to grow steadily at a CAGR of 8.5% through 2034. The country's leadership stems from widespread pet ownership, a heightened focus on animal wellness, and rising awareness about early diagnosis and specialized orthopedic treatments among pet owners.

To strengthen their presence in the modular substation space, companies are adopting smart grid technologies and investing in digital infrastructure integration. Strategic collaborations with power utilities and infrastructure developers are helping secure large-scale deployments. Firms are focusing on modular design innovations that reduce setup time and cost while improving adaptability in both urban and rural applications. Increased emphasis on compact, gas-insulated units enhances performance in space-constrained settings. Additionally, key players prioritize localization of production to mitigate tariff impacts and ensure supply chain resilience. Investments in remote monitoring tools and predictive maintenance platforms boost reliability and operational uptime, making modular substations more appealing for rapid grid modernization and renewable energy integration.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership and increased spending on veterinary care
    • 3.2.1.2 Growing awareness of animal welfare and orthopedic disorders
    • 3.2.1.3 Advancements in regenerative medicine and pain management for animals
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of veterinary orthopedic treatments
    • 3.2.2.2 Regulatory hurdles for new therapies and pharmaceuticals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Country-wise response
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (Cost of manufacturing)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (Cost to consumers)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Biologics
  • 5.2.1 Stem cells
  • 5.2.2 Platelet-rich plasma (PRP)
  • 5.2.3 Other biologics
• 5.3 Viscosupplements
• 5.4 Pharmaceuticals
  • 5.4.1 Steroids
  • 5.4.2 NSAIDs
  • 5.4.3 Other pharmaceuticals

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
• 6.3 Livestock animals

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Osteoarthritis
• 7.3 Degenerative joint disease
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable
• 8.4 Topical

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospitals
• 9.3 Veterinary clinics
• 9.4 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Ardent Animal Health
• 11.2 Bimeda
• 11.3 Bioiberica
• 11.4 Boehringer Ingelheim
• 11.5 Ceva Sante Animale
• 11.6 Contipro
• 11.7 Contura Vet US
• 11.8 Elanco Animal Health
• 11.9 Hester Biosciences
• 11.10 MEDREGO
• 11.11 Merck
• 11.12 PetVivo Holdings
• 11.13 T-Cyte Therapeutics
• 11.14 Vetoquinol
• 11.15 VetStem
• 11.16 Virbac
• 11.17 Zoetis